ORIC - Oric Pharmaceuticals, Inc.

QQQ $ 633.20 nm (nm)

DIA $ 475.83 $ -1.36 (-0.29 %)

SPY $ 684.43 nm (nm)

TLT $ 90.42 nm (nm)

GLD $ 371.67 $ 7.13 (1.96 %)

Previous Close

$ 13.34

Open

$ 12.82

Bid

$ 12.80 x 1,000

Ask

$ 13.75 x 75

Day's Range

-- - --

52 Week Range

$ 3.90 - $ 14.93

Volume

908,590

Average Volume

Market Cap

1.3B

Beta (5Y Monthly)

$ 1.04

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-05-2025	03-31-2025	10-Q
3	02-18-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-06-2024	03-31-2024	10-Q
7	03-11-2024	12-31-2023	10-K
8	11-06-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	03-16-2023	12-31-2022	10-K
12	11-07-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-09-2022	03-31-2022	10-Q
15	03-21-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-10-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	03-23-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	05-20-2020	03-31-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ORIC Pharmaceuticals Highlights Preclinica...
10/27/2025 12:41:50

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mecha...

Guggenheim Assumes ORIC Pharmaceuticals at...
09/04/2025 14:12:53

Guggenheim analyst Brad Canino assumes ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $18.

JP Morgan Maintains Overweight on ORIC Pha...
08/14/2025 15:45:05

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...

HC Wainwright & Co. Maintains Buy on ORIC ...
08/14/2025 11:22:39

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price ta...

Guggenheim Reiterates Buy on ORIC Pharmace...
08/13/2025 13:38:10

Guggenheim analyst Michael Schmidt reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $18 price target.

ORIC Pharmaceuticals Q2 EPS $(0.47) Misses...
08/12/2025 20:33:34

Ladenburg Thalmann Initiates Coverage On O...
07/08/2025 18:47:31

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and ann...

crude-oil-falls-over-1-best-buy-reports-downbeat-results

Crude Oil Falls Over 1%; Best Buy Reports ...
05/29/2025 17:13:42

oric-pharmaceuticals-touts-positive-efficacy-safety-data-from-early-stage-prostate-cancer-candidate-raises-capital

ORIC Pharmaceuticals Touts Positive Effica...
05/29/2025 15:15:54

ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing p...

veeva-systems-elf-beauty-c3ai-brp-and-other-big-stocks-moving-higher-on-thursday

Veeva Systems, e.l.f. Beauty, C3.ai, BRP A...
05/29/2025 14:11:52

12 Health Care Stocks Moving In Thursday's...
05/29/2025 12:07:57

why-nvidia-shares-are-trading-higher-by-over-5-here-are-20-stocks-moving-premarket

Why Nvidia Shares Are Trading Higher By Ov...
05/29/2025 09:44:58

12 Health Care Stocks Moving In Wednesday'...
05/28/2025 21:05:47

ORIC Pharma Announces $125M Private Placem...
05/28/2025 20:17:08

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors,...

ORIC Pharma Announces Preliminary Efficacy...
05/28/2025 20:15:22

Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending...

ORIC Pharmaceuticals To Present Data From ...
05/27/2025 12:08:44

HC Wainwright & Co. Maintains Buy on ORIC ...
05/09/2025 13:12:43

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price ta...

Oppenheimer Maintains Outperform on ORIC P...
05/06/2025 13:22:12

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price targ...

Cantor Fitzgerald Reiterates Overweight on...
05/06/2025 13:06:16

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) from Overweight to Overweight.

ORIC Pharmaceuticals Q1 EPS $(0.42) Beats ...
05/05/2025 20:16:59

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...